Literature DB >> 30102660

Cardiac status of perinatally HIV-infected children: assessing combination antiretroviral regimens in observational studies.

Paige L Williams1,2, Katharine Correia1, Brad Karalius2, Russell B Van Dyke3, James D Wilkinson4, William T Shearer5, Steven D Colan6, Steven E Lipshultz7.   

Abstract

OBJECTIVE: To evaluate potential adverse associations of individual antiretroviral medications used in combination antiretroviral therapy regimens on cardiac structure and function in youth with perinatally-acquired HIV infection (PHIV).
DESIGN: PHIV youth (N = 325) enrolled in a prospective multisite cohort study had a single echocardiogram at age 7-16 years to evaluate cardiac function and structure.
METHODS: We applied several statistical approaches to evaluate associations between use of 18 individual antiretroviral medications with Z-scores for 11 measures of left ventricular function and structure. These included simultaneously evaluating all antiretroviral medications in adjusted linear regression models controlling for the false discovery rate (FDR), applying hierarchical models to estimate individual antiretroviral medication effects as deviations from drug class means, and evaluating latent measures of cardiac function and structure underlying multiple echocardiographic parameters.
RESULTS: Youth taking combination regimens with a protease inhibitor (69%) had significantly better cardiac function than those on other regimens. After FDR control and adjustment for other antiretroviral medications, no individual antiretroviral medication was significantly associated with any measure of left ventricular function, but zidovudine was associated with higher adjusted mean Z-scores for one measure of left ventricular structure (end-systolic wall stress). Factor analysis identified three latent factors: heart function, heart size, and heart wall stress. Lopinavir was associated with better heart function scores, whereas zidovudine was associated with higher wall stress scores. Zidovudine and nevirapine were associated with higher heart size factor scores.
CONCLUSIONS: Despite cardioprotective effects of combination regimens in PHIV youth, individual antiretroviral medications were associated with altered cardiac structure, which could progress to symptomatic cardiomyopathy in adulthood.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30102660      PMCID: PMC6519135          DOI: 10.1097/QAD.0000000000001988

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  38 in total

1.  Zidovudine treatment in HIV-infected pregnant women is associated with fetal cardiac remodelling.

Authors:  Laura García-Otero; Marta López; Olga Gómez; Ana Goncé; Mar Bennasar; Josep Maria Martínez; Brenda Valenzuela-Alcaraz; Mérida Rodriguez-López; Marta Sitges; Montserrat Loncà; Bart Bijnens; Fàtima Crispi; Eduard Gratacós
Journal:  AIDS       Date:  2016-06-01       Impact factor: 4.177

Review 2.  Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009).

Authors:  Marie-Pierre de Béthune
Journal:  Antiviral Res       Date:  2009-09-23       Impact factor: 5.970

Review 3.  Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance.

Authors:  Annemarie M J Wensing; Noortje M van Maarseveen; Monique Nijhuis
Journal:  Antiviral Res       Date:  2009-10-22       Impact factor: 5.970

4.  Prevalence of elevated cholesterol and associated risk factors among perinatally HIV-infected children (4-19 years old) in Pediatric AIDS Clinical Trials Group 219C.

Authors:  John Farley; Philimon Gona; Marilyn Crain; Joseph Cervia; James Oleske; George Seage; Jane Lindsey
Journal:  J Acquir Immune Defic Syndr       Date:  2005-04-01       Impact factor: 3.731

Review 5.  Surveillance monitoring for safety of in utero antiretroviral therapy exposures: current strategies and challenges.

Authors:  Rebecca M Zash; Paige L Williams; Jeanne Sibiude; Hermione Lyall; Fatima Kakkar
Journal:  Expert Opin Drug Saf       Date:  2016-09-06       Impact factor: 4.250

6.  Cardiac dysfunction and mortality in HIV-infected children: The Prospective P2C2 HIV Multicenter Study. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection (P2C2 HIV) Study Group.

Authors:  S E Lipshultz; K A Easley; E J Orav; S Kaplan; T J Starc; J T Bricker; W W Lai; D S Moodie; G Sopko; S D Colan
Journal:  Circulation       Date:  2000-09-26       Impact factor: 29.690

7.  Association of hypercholesterolemia incidence with antiretroviral treatment, including protease inhibitors, among perinatally HIV-infected children.

Authors:  Katherine Tassiopoulos; Paige L Williams; George R Seage; Marilyn Crain; James Oleske; John Farley
Journal:  J Acquir Immune Defic Syndr       Date:  2008-04-15       Impact factor: 3.731

8.  Cardiac Effects of Highly Active Antiretroviral Therapy in Perinatally HIV-Infected Children: The CHAART-2 Study.

Authors:  Steven E Lipshultz; James D Wilkinson; Bruce Thompson; Irene Cheng; David A Briston; William T Shearer; E John Orav; Joslyn A Westphal; Tracie L Miller; Steven D Colan
Journal:  J Am Coll Cardiol       Date:  2017-10-31       Impact factor: 24.094

9.  A hierarchical modeling approach for assessing the safety of exposure to complex antiretroviral drug regimens during pregnancy.

Authors:  Katharine Correia; Paige L Williams
Journal:  Stat Methods Med Res       Date:  2017-10-03       Impact factor: 3.021

Review 10.  Cardiac effects in perinatally HIV-infected and HIV-exposed but uninfected children and adolescents: a view from the United States of America.

Authors:  Steven E Lipshultz; Tracie L Miller; James D Wilkinson; Gwendolyn B Scott; Gabriel Somarriba; Thomas R Cochran; Stacy D Fisher
Journal:  J Int AIDS Soc       Date:  2013-06-18       Impact factor: 5.396

View more
  1 in total

1.  Rethinking COVID-19 in children: Lessons learned from pediatric viral and inflammatory cardiovascular diseases.

Authors:  Paul Barach; Steven E Lipshultz
Journal:  Prog Pediatr Cardiol       Date:  2020-05-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.